Igniting Drug Discovery in Africa: A Renewed Partnership

By Staff Writer

November 30, 2023

The Power of Partnership

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and H3D Foundation have recently announced a renewed three-year phase of their partnership. The renewed partnership for drug discovery in Africa aim is to enhance the skills and capacity needed to drive increased research and development of new medicines in Africa. This partnership is crucial in addressing the imbalance of medical research in Africa, where despite 20% of the global burden of disease, only 2% of medical research focused on new infections originates.

Renewed Partnership for Drug Discovery in Africa

According to Richard Amewu, Principal Investigator, Drug Innovation Group, University of Ghana, the IFPMA partnership with H3D Foundation has brought credibility to the continent, unlocking further international investment in drug discovery research and development. The continuation of this partnership will address critical gaps in research capacity, capabilities, and infrastructure, providing momentum to the African drug discovery ecosystem.

Strengthening Health Systems and Expanding Innovation

The next three years will see the partnership tackling issues such as strengthening health systems, expanding the innovation ecosystem value chain, and addressing barriers for African scientists to break new ground within the drug discovery-related sciences. As Prof Kelly Chibale, Chairman and CEO of H3D-F and Founder and Director of H3D, points out, the partnership has enabled the scaling up of initiatives and catalysed interactions with representatives from the innovative pharmaceutical industry, at both local and international levels.

A Sustainable Investment in Africa’s Health Ecosystem

Greg Perry, Assistant Director General, IFPMA, believes that attracting, developing, and nurturing scientific talent and innovation at a local level will help ensure that Africa is part of the innovation ecosystem value chain. The continued partnership with H3D Foundation is seen as a sustainable investment in Africa’s health ecosystem.

In conclusion, the renewed partnership for drug discovery in Africa between IFPMA and the H3D Foundation promises to be a great step toward positioning Africa as a worldwide participant in innovative pharmaceutical R&D. The intent is to have a long-term impact on the continent’s health ecosystem by constructing infrastructure and improving the capabilities of African scientists and researchers.

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.